Vertex Pharmaceuticals Receives FDA Approval for Journavx in Diabetic Peripheral Neuropathic Pain

Vertex Pharmaceuticals today announced that the FDA has approved Journavx (suzetrigine) for the treatment of adults with diabetic peripheral neuropathic pain (DPNP). In Phase 3 trials, Journavx demonstrated a statistically significant reduction in average daily pain score compared to placebo. This approval expands Journavx's indications beyond acute pain to include DPNP, a chronic pain condition affecting millions of patients with diabetes. Journavx is a highly selective Nav1.8 sodium channel inhibitor that provides pain relief without the addiction risk of opioids.